Baker BROS. Advisors LP Decreases Stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Baker BROS. Advisors LP cut its stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 96.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 83,055 shares of the company's stock after selling 1,993,345 shares during the period. Baker BROS. Advisors LP owned about 2.60% of Aligos Therapeutics worth $719,000 at the end of the most recent quarter.

Separately, Armistice Capital LLC grew its holdings in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company's stock worth $2,540,000 after acquiring an additional 363,000 shares in the last quarter. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock traded up $0.21 during midday trading on Monday, hitting $25.72. 546,964 shares of the company's stock were exchanged, compared to its average volume of 90,829. Aligos Therapeutics, Inc. has a 12 month low of $6.76 and a 12 month high of $30.00. The firm has a 50-day moving average of $11.83 and a two-hundred day moving average of $12.61. The company has a market cap of $92.28 million, a PE ratio of -1.98 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The firm had revenue of $1.27 million for the quarter, compared to analysts' expectations of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period in the previous year, the company posted ($10.25) earnings per share. As a group, equities analysts expect that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).